PDF Cover

Givosiran Sodium Market

The market for Givosiran Sodium was estimated at $470 million in 2024; it is anticipated to increase to $1.43 billion by 2030, with projections indicating growth to around $3.62 billion by 2035.

Report ID:DS1802244
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Pharmaceutical
Givosiran Sodium
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Givosiran Sodium Market Outlook

Revenue, 2024

$470M

Forecast, 2034

$3.01B

CAGR, 2025 - 2034

20.4%

The Givosiran Sodium industry revenue is expected to be around $565.6 million in 2025 and expected to showcase growth with 20.4% CAGR between 2025 and 2034. With the progress in this field and the increasing prevalence of acute hepatic porphyria alongside advancements in precision medicine research driving it forward the popularity of Givosiran Sodium comes as no surprise. Healthcare providers are finding it to be increasingly beneficial enhancing patient results significantly. This potent RNA interference treatment is making waves as a force reshaping the healthcare sector. Its exceptional effectiveness and enhanced patient adherence validate its continued significance, in the industry.

A new medication called Givosiran Sodium is causing a buzz in the world for its important role in treating acute hepatic porphyria. This drug is soluble in water. Is given through subcutaneous administration to block the activity of the ALAS1 enzyme and decrease the buildup of harmful substances that affect the nervous system. One of the shifts boosting its popularity is the trend towards customized treatment and the increasing favorability, towards targeted therapy.

Givosiran Sodium market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Givosiran Sodium Market Outlook

Market Key Insights

  • The Givosiran Sodium market is projected to grow from $469.8 million in 2024 to $3.01 billion in 2034. This represents a CAGR of 20.4%, reflecting rising demand across Acute Hepatic Porphyrias (AHP) Management, Genetic Disorder Therapies, and Research & Development In Rare Diseases.

  • Alnylam Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc. are among the leading players in this market, shaping its competitive landscape.

  • U.S. and Germany are the top markets within the Givosiran Sodium market and are expected to observe the growth CAGR of 19.6% to 28.6% between 2024 and 2030.

  • Emerging markets including Brazil, South Africa and Vietnam are expected to observe highest growth with CAGR ranging between 15.3% to 21.2%.

  • Transition like Expansion into Rare Disease Treatment is expected to add $79 million to the Givosiran Sodium market growth by 2030.

  • The Givosiran Sodium market is set to add $2.5 billion between 2024 and 2034, with manufacturer targeting Genetic Disorder & Others Application projected to gain a larger market share.

  • With

    rising acute hepatic porphyria diagnosis rates and advancing rnai therapeutic innovation, and

    Shift Toward Prophylactic Management of Rare Metabolic Disorders in Specialty Care Settings, Givosiran Sodium market to expand 540% between 2024 and 2034.

givosiran sodium market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Givosiran Sodium - Country Share Analysis

Opportunities in the Givosiran Sodium

Strategic alliances and partnerships with research institutions and pharmaceutical companies could also greatly enhance the prospects of Givosiran Sodium by advancing treatment protocols and patient outcomes for hepatic porphyria while deepening our knowledge in this area—a pivotal driver, for the growth of Givosiran Sodium moving forward.

Growth Opportunities in North America and Europe

In North America's landscape where rare genetic diseases are increasingly prevalent and the market for Givosiran Sodium is expanding significantly due to advancements in gene therapy techniques and the rise of biotech research investments in recent years. The regions pharmaceutical sector has been transformed dynamically over the decade with an aging population and increasing health consciousness playing crucial roles in driving demand. Competition in the market is fierce with companies, like Alnylam Pharmaceuticals taking the lead in developing and distributing crucial treatments. Establishing collaborations with government entities and non profit organizations can give companies a significant edge in the competitive landscape. The United States leads the market because of its advanced healthcare system and higher instances of acute hepatic porphyria cases. However Canada is also poised for increased demand for Givosiran Sodium fueled by its relationship with the US and a steady uptick, in health related issues.
Western Europe is seen as a market for Givosiran Sodium due to its diverse population and high rates of rare genetic conditions coupled with strong healthcare facilities driving growth in this sector Orion Pharma and Sanofi are leading players in Europe's market scenario by promoting creativity and making advanced genetic treatments accessible The teamwork among pharmaceutical companies researchers and government agencies helps to speed up drug approvals leading to more chances for Givosiran Sodium, in the market.

Market Dynamics and Supply Chain

01

Driver: Rising Acute Hepatic Porphyria Diagnosis Rates and Advancing RNAi Therapeutic Innovation

Growing awareness and improved diagnostic protocols for acute hepatic porphyria (AHP) are also expanding the identifiable patient pool eligible for givosiran sodium therapy. Enhanced genetic screening, better physician education, and inclusion of porphyria testing in unexplained abdominal pain cases are also reducing historical underdiagnosis. Parallel to this, also advances in RNA interference (RNAi) drug platforms have also increased clinical confidence in long-term gene-silencing therapies. Improvements in hepatocyte-targeted delivery, durability of response, and safety monitoring frameworks have also positioned givosiran as a viable chronic prophylactic option rather than episodic treatment. These dual trends are also particularly relevant in rare-disease therapeutics, where validated platform technologies reduce regulatory uncertainty and accelerate payer acceptance. Together, expanding diagnosis rates and maturing RNAi technology are also driving sustained uptake in specialized metabolic and genetic disorder treatment centers globally.
The market for givosiran sodium is also driven by a clear shift from symptomatic crisis management toward preventive treatment in rare metabolic disorders. Clinicians increasingly prioritize reducing attack frequency, hospitalization rates, and long-term organ damage in AHP patients. Givosiran’s monthly dosing and demonstrated attack reduction align well with this preventive care model. Specialty centers are also integrating prophylactic RNAi therapies into standardized care pathways, supporting steady demand growth. This trend is also reinforced by patient advocacy efforts emphasizing quality-of-life improvement rather than reactive treatment alone.
02

Restraint: Regulatory Hurdles

Despite the advantages of Givosiran Sodium in treating acute hepatic porphyrias it faces regulatory hurdles that impede its market expansion. For example obtaining clearance for rare disease therapies such, as Givosiran Sodium typically entails intricate and time consuming procedures that could discourage new players or hinder the progress of current market participants. Meeting the demand for providing information from clinical studies and following strict safety and effectiveness guidelines alongside keeping up with regulatory changes can lead to higher operational expenses and delays in getting the product to market on time – ultimately restricting its appeal, to consumers.
03

Opportunity: Broadening Footprint in Developing Markets and Innovation in Drug Delivery Methods

The use of Givosiran Sodium in the field of life sciences as a remedy for acute hepatic porphyria is well known and it has a significant opportunity to broaden its market reach in countries like India, Brazil, and South Africa where there is an increasing incidence of acute hepatic porphyria. These emerging markets offer a prospect, for the expansion of Givosiran Sodium.
In the field of drug delivery technologies significant progress has been made that puts Givosiran Sodium in a position to take advantage of this trend. Breakthroughs, like nano coating or creating lasting versions of the medication have the potential to greatly enhance the markets reception and usage of Givosiran Sodium.
04

Challenge: High Treatment Costs

In addition to regulatory constraints, the steep price of Givosiran Sodium therapy poses another significant challenge. Owing to the high costs associated with research and development, production, and marketing of orphan drugs, the costs are often passed onto the patients who require the therapy. This can restrict the accessibility of the treatment to a limited patient pool who can afford the cost, subsequently influencing the market demand.

Supply Chain Landscape

1

Raw Material Suppliers

BASF SEDow Chemicals
2

Intermediate Product Manufacturers

BioVectraWuXi PharmaTech
3

API Manufacturers

SanofiAlnylam Pharmaceuticals
4

End User Industry

PharmaceuticalsResearch InstitutesHealthcare
Givosiran Sodium - Supply Chain

Use Cases of Givosiran Sodium in Acute Hepatic Porphyrias (AHP) Management & Research & Development In Rare Diseases

Acute Hepatic Porphyrias (AHP) Management : In clinical practice, subcutaneous injectable givosiran sodium is predominantly used for long-term AHP management in specialty hospitals and metabolic disorder clinics. It is administered monthly to suppress hepatic ALAS1 expression, significantly reducing acute attack frequency and hospitalization rates. The therapy offers clear advantages in prophylactic disease control and quality-of-life improvement. Alnylam Pharmaceuticals leads this application segment, leveraging strong RNAi expertise, established reimbursement pathways, and deep penetration across rare disease specialty networks.
Genetic Disorder Therapies : Within genetic disorder therapies, givosiran sodium is mainly utilized as a targeted RNAi-based injectable treatment addressing inherited metabolic dysfunctions. It is prescribed by genetic specialists to manage disease progression at the molecular level rather than symptomatically. Its precision gene-silencing capability provides a strong advantage over conventional therapies. Alnylam Pharmaceuticals dominates this space due to its pioneering RNA interference platform, robust clinical data, and leadership in commercializing genetic medicines for rare inherited disorders.
Research & Development In Rare Diseases : In research and development settings, givosiran sodium is primarily used as a reference RNAi compound for translational and clinical research in rare hepatic and metabolic diseases. Academic institutes and biotech companies study its gene-silencing mechanism to advance next-generation RNA-based therapies. The key advantage lies in its validated delivery and safety profile. Alnylam remains the central market player, supported by strong intellectual property, strategic collaborations, and sustained investment in rare disease innovation.

Recent Developments

Recent developments for givosiran sodium (GIVLAARI) reinforce its strategic role in RNAi therapy and rare disease treatment. Strong commercial growth and positive clinical evidence from ENVISION bolster market confidence, supporting broader payer adoption and specialty care integration. This aligns with the trend toward prophylactic metabolic disorder management and increased diagnostic rates for acute hepatic porphyria. Continued focus on global market expansion and real-world evidence generation should sustain demand and strengthen long-term therapeutic positioning in precision medicine.

October 2025 : GIVLAARI (givosiran) continued to contribute to the company’s rare disease portfolio, with approvals in the U.S., Brazil, and the European Union. The update highlighted ongoing commercial expansion and inclusion in global net product revenue
July 2025 : Alnylam Provides Mid-Year 2025 Results and 2026 Guidance Under Alnylam 2030”Strategic Plan Preliminary financial results for the first half of 2025 showed GIVLAARI’s global net product revenue growth, contributing to an expanded revenue outlook for 2026 under the company’s long-term strategy.
August 2023 : Results from the pivotal Phase 3 ENVISION trial for givosiran were published, demonstrating significant efficacy in reducing acute hepatic porphyria attacks and strengthening clinical evidence supporting long-term use.

Impact of Industry Transitions on the Givosiran Sodium Market

As a core segment of the Pharmaceutical industry, the Givosiran Sodium market develops in line with broader industry shifts. Over recent years, transitions such as Expansion into Rare Disease Treatment and Precision Medicine Approach have redefined priorities across the Pharmaceutical sector, influencing how the Givosiran Sodium market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Expansion into Rare Disease Treatment

The transition towards Givosiran Sodium as a treatment for hepatic porphyrias marks a pivotal shift in the pharmaceutical landscape, positioning it as a frontrunner in the development of therapies for rare diseases. This strategic focus not only enhances the treatment options available for patients suffering from these uncommon genetic conditions but is also projected to drive an additional $79 million in market growth by 2030. As the industry increasingly prioritizes specialized therapies, Givosiran Sodium exemplifies the potential for targeted treatments to transform patient outcomes and elevate public health standards. This evolution underscores a broader commitment to addressing neglected illnesses, ultimately fostering innovation and expanding the pharmaceutical pipeline.
02

Precision Medicine Approach

Another critical transition in the Givosiran Sodium industry centers on adopting a precision medicine approach. With Givosiran Sodium, treatment plans can be tailored for individual patients, leading to better outcomes. This practice has underlined the trend towards personalized medicine. The precision medicine methodology has observed a significant uptake across the healthcare sector, with impacts spanning diagnostics,digital therapeutics, and patient monitoring.